Patents by Inventor Peter Qinhua HUANG

Peter Qinhua HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20220024939
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • EGFR INHIBITOR COMPOUNDS
    Publication number: 20210395230
    Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 23, 2021
    Applicant: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20210330651
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS
    Publication number: 20210317124
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 14, 2021
    Inventors: Peter Qinhua Huang, Brant Clayton Boren, Kevin Duane Bunker, Hui Liu, Sunil Paliwal
  • L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs
    Patent number: 11124518
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 21, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Brant Clayton Boren, Kevin Duane Bunker, Hui Liu, Sunil Paliwal
  • EGFR inhibitor compounds
    Patent number: 11098030
    Abstract: Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Peter Qinhua Huang, Sunny Abraham, Joseph Robert Pinchman, Chad Daniel Hopkins, Deborah Helen Slee
  • Estrogen receptor modulators
    Patent number: 11065234
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • Estrogen receptor modulators
    Patent number: 11065233
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: July 20, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20210139482
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: February 26, 2019
    Publication date: May 13, 2021
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20210115058
    Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Peter Qinhua Huang, Mehmet Kahraman, Kevin Duane Bunker
  • Bicyclic compounds
    Patent number: 10975035
    Abstract: Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 13, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Chuangxing Guo, Mark Charles Grier, Chad Daniel Hopkins, Joseph Robert Pinchman, Deborah Helen Slee, Peter Qinhua Huang, Mehmet Kahraman
  • ACRYLIC ACID ANALOGS
    Publication number: 20210094899
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 1, 2021
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Kevin Duane Bunker, Sayee Gajanan Hegde, Chad Daniel Hopkins
  • Estrogen receptor modulators
    Patent number: 10959989
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 30, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Deborah Helen Slee, Sayee Gajanan Hegde, Chad Daniel Hopkins, Kevin Duane Bunker, Joseph Robert Pinchman, Rakesh Kumar Sit
  • Spirocyclic compounds
    Patent number: 10934304
    Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: March 2, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Mehmet Kahraman, Kevin Duane Bunker
  • ESTROGEN RECEPTOR MODULATORS FOR TREATING MUTANTS
    Publication number: 20210038573
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Application
    Filed: August 4, 2020
    Publication date: February 11, 2021
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate
  • BENZAMIDE COMPOUNDS
    Publication number: 20210009543
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Application
    Filed: January 8, 2019
    Publication date: January 14, 2021
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • BENZAMIDE COMPOUNDS
    Publication number: 20200339605
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Application
    Filed: January 8, 2019
    Publication date: October 29, 2020
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • BENZAMIDE COMPOUNDS
    Publication number: 20200338071
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Application
    Filed: January 8, 2019
    Publication date: October 29, 2020
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • Methods for cross coupling
    Patent number: 10793504
    Abstract: Methods of preparing substituted bicyclo[0.1.1.1]pentane compounds of Formula (I) comprise reacting a compound of Formula (A) with a compound of Formula (B) in the presence of a first transition metal catalyst selected from a palladium catalyst and a nickel catalyst, where the variables R1, R2, X1 and X2 are as described herein.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 6, 2020
    Assignee: Recurium IP Holdings, LLC
    Inventors: Joseph Robert Pinchman, Chad Daniel Hopkins, Kevin Duane Bunker, Peter Qinhua Huang
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20200268714
    Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Application
    Filed: January 6, 2020
    Publication date: August 27, 2020
    Inventors: Peter Qinhua Huang, Mehmet Kahraman, Deborah Helen Slee, Kevin Duane Bunker, Chad Daniel Hopkins, Joseph Robert Pinchman, Sunny Abraham, Rakesh Kumar Sit, Daniel Lee Severance